Form 6-K ASCENTAGE PHARMA GROUP For: May 28

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of May 2026

 

Commission File Number: 001-42484

 

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

 

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐ 

 

 

EXPLANATORY NOTE

 

On May 28, 2026, Ascentage Pharma Group International issued an announcement entitled “Purchase of Shares by the Trustee for the Purpose of the 2022 RSU Scheme”. A copy of the press release is furnished as Exhibit 99.1.

 

 

INDEX TO EXHIBITS

 

Exhibit
Number		Exhibit Title
99.1		Announcement dated May 28, 2026

 

  

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	ASCENTAGE PHARMA GROUP INTERNATIONAL
Date: May 28, 2026	/s/ Dajun Yang
	Name:	Dajun Yang
	Title:	Chief Executive Officer

 

 

ATTACHMENTS / EXHIBITS

ANNOUNCEMENT DATED MAY 28, 2026

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• B.Riley Starts Ascentage Pharma Group (AAPG) at Buy
• Hilton Grand Vacations Completes $300 Million Term Note Securitization
• Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit